Fiber SupplementsGuide6 min
GLP-1 Supplements: What's Actually in Them
Fiber, a mineral, a plant alkaloid and some bacteria. What the panels list, what the strongest research reports for each, and what FDA does not check.
TL;DR
Key takeaways
- The category resolves to four things: fiber, a mineral, a plant alkaloid and probiotic bacteria. One panel we read was a three-strain probiotic capsule with 211 mg of chicory inulin; another sold on 6 grams of fiber per serving. Nothing on these panels is a receptor agonist, and no seller claims one is.
- FDA does not approve any of it before sale. Its own consumer page states that under DSHEA the agency lacks the authority to approve dietary supplements before they are marketed, and answers "No" to whether it routinely analyses their content.
- Berberine's best estimate is under a kilogram. A 2026 systematic review and meta-analysis of 23 randomized trials in the International Journal of Obesity reports a mean weight reduction of 0.88 kg versus control.
- Chromium picolinate has a Cochrane review, and it is not encouraging. Across nine trials the difference was 1.1 kg, which the authors themselves call of debatable clinical relevance on low-quality evidence, concluding there is no reliable evidence to inform firm decisions.
- Berberine interacts with prescription medicines. NCCIH names cyclosporine specifically, describes berberine as likely unsafe for infants and possibly unsafe in pregnancy and breastfeeding, and lists nausea, abdominal pain, bloating, constipation and diarrhea among reported side effects.
Pick by your situation
| If your situation is… | Pick | Why |
|---|---|---|
| You saw one advertised as supporting your body's own GLP-1 | Read it as a structure/function claim | That phrasing is what the law permits without FDA review. The firm must hold substantiation but never has to show it to FDA. |
| You want the constipation to stop | Fiber, ramped slowly and with fluid | That is the one mechanism on this shelf that does what the box implies, and the food-first version costs nothing. |
| You are choosing between a supplement and more protein | Protein | Appetite is the constraint on a GLP-1, and protein intake is the decision that protects muscle while weight comes off. |
| You already take a prescription medicine | Show the bottle to your pharmacist first | Berberine is documented to interact with cyclosporine, and no panel tells your pharmacist how much is in a serving. |
| You are pregnant, breastfeeding, or buying for a child | Do not, without a clinician saying otherwise | NCCIH describes berberine as likely unsafe for infants and possibly unsafe in pregnancy and breastfeeding. |
| The prescription is out of reach and this is the substitute | Your prescriber, about coverage | The gap between a kilogram and a fifth of body weight is not a gap a capsule closes. |
Each pick is one of the products compared below — a shortcut by situation, not a separate recommendation.
There is now a shelf of capsules, gummies and stick packs sold as support, and it exists for an honest reason: the prescriptions are expensive, frequently out of reach, and sometimes out of stock. Nobody should feel foolish for reading the box.
So read the box. That is the whole method here — what is printed on these panels, and what the research on each of those ingredients actually says.
What is in them, in substance
We read the ingredient panels on current listings sold as GLP-1 support. Stripped of the packaging, they resolve into a short list of things.
One was a capsule holding a three-strain probiotic blend plus 211 mg of chicory inulin — a prebiotic fiber. Another was a powdered blend selling on 6 grams of fiber per serving. The names that recur across the rest of the shelf are berberine, chromium, a such as glucomannan or , green tea extract, cinnamon and inositol.
That is the substance of this category: fiber, a mineral, a plant alkaloid and some bacteria. None of it is a receptor agonist, and no seller on the shelf claims otherwise — which is why the marketing sentence is almost always about supporting the GLP-1 your body already makes, rather than supplying any.
The sentence doing the work, and the law behind it
"Supports your body's own GLP-1" is a structure/function claim, and FDA's questions and answers on dietary supplements explains exactly what that permits. Three lines from that page are the ones worth carrying around:
- "Under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed." A product on the shelf has not been cleared by anyone.
- A firm making a structure/function claim "must have substantiation that the claim is truthful and not misleading" — but it does not have to show that substantiation to FDA before or after selling the product.
- Asked whether it routinely analyses the content of dietary supplements, FDA's answer is one word: "No."
That is also why every such label carries the small-print disclaimer that the statements have not been evaluated by FDA and the product is not intended to diagnose, treat or prevent any disease. The disclaimer is not a formality — it is the boundary of the claim.
Ingredient by ingredient, at the best evidence available
| Ingredient | What the strongest available research reports |
|---|---|
| Berberine | A 2026 systematic review and meta-analysis of 23 randomized trials found a mean weight reduction of 0.88 kg versus control |
| Chromium picolinate | A Cochrane review of nine trials found a mean difference of 1.1 kg, described by its own authors as of debatable clinical relevance, on low-quality evidence |
| Glucomannan | A systematic review of six trials found short-term weight reduction in adults in three of them, and no favourable effect on BMI in any |
| Green tea extract | NCCIH describes a modest effect of catechins and caffeine on body weight, alongside reports of liver injury in people using the extract in tablet or capsule form |
| Fiber generally | Real, and the one thing on this list that genuinely earns a place in a small-appetite diet — as food volume and regularity, not as a weight-loss agent |
Those are the honest numbers, and each is worth reading in the source. The berberine meta-analysis in the International Journal of Obesity reports −0.88 kg (95% CI −1.36 to −0.39) and closes by asking future trials to report purity, potency and gram amounts, and to fix the widespread lack of blinding. NCCIH's berberine page adds the detail the supplement aisle leaves out: effects appeared mainly in people taking more than a gram a day for more than eight weeks, many of the underlying studies carried a high risk of bias, and most were conducted in Asian countries with participants who already had diabetes or fatty liver disease.
The Cochrane review of chromium picolinate is blunter still. Across all doses studied it found 1.1 kg of difference after 12 to 16 weeks, graded low quality, and its authors' conclusion is a single sentence: "We found no current, reliable evidence to inform firm decisions about the efficacy and safety of CrP supplements in overweight or obese adults."
The glucomannan review found some short-term effect on body weight in adults and none on BMI, from six trials. And NCCIH's green tea page pairs its modest finding with a safety note that matters more than the finding does.
The scale problem
Put those beside the drugs these products are named after and the gap is not a matter of degree.
In SURMOUNT-5, 751 adults with obesity and without type 2 diabetes lost a mean of 20.2% of body weight on and 13.7% on over 72 weeks. The best meta-analytic estimate for berberine is under a kilogram. These are not two points on one scale; they are two different kinds of intervention, and only one of them was studied for this purpose in this population.
What the label does not tell you
Worth raising at your next visitFrom this guide
Two things to raise with your prescriber and your pharmacist before you start any of this. Berberine is documented to interact with prescription medicines — NCCIH names cyclosporine specifically — and it is described as likely unsafe for infants and possibly unsafe in pregnancy and breastfeeding. And the gastrointestinal side effects reported for berberine are nausea, abdominal pain, bloating, constipation and diarrhea: the same list you may already be managing.
There is also the plainer problem NCCIH states on its weight control page: analyses of dietary supplements sometimes find differences between labelled and actual ingredients, and FDA has found weight-loss products tainted with prescription drug ingredients. That page is dated — it was last updated in September 2017 — but the mechanism it describes has not changed, and FDA's own standing page on unapproved GLP-1 drugs used for weight loss describes the modern version of the same market.
If a product is doing something dramatic, the interesting question is what is in it.
Where the money actually goes further
None of this means nothing on the shelf is worth buying. It means buying it for what it does rather than for the name on the front.
- Fiber, ramped slowly and with fluid, for the constipation that sends most people shopping in the first place — the mechanism there is real and the food-first version is cheaper than any capsule. Our fiber supplement shelf is the paid version of the same idea.
- Protein, because appetite is the constraint and protein-first eating is the decision that protects what you do not want to lose. The protein powder shelf is for the eating occasions where food is not happening.
- Electrolytes, for the specific case of low intake and fluid loss — with the caveats in our comparison, not as a daily default. The electrolyte powder shelf labels each one by use case and discloses the sodium; the kidney, heart and blood-pressure caveats are a prescriber conversation.
- Nothing at all, which is a legitimate answer. Two sessions a week of resistance training has better evidence behind it than everything in this article's table combined, and it is free.
If the reason you are reading this is that the prescription is out of reach, that is a conversation with your prescriber about coverage and options — not a shelf problem, and not one a capsule solves. The related question of whether a patch can deliver the drug through skin is settled on physical grounds, and we worked through it separately.
Your next step
If the money is going somewhere, protein is where it goes furthest.
Frequently asked
The questions that keep coming up
What is actually in a GLP-1 support supplement?
Fiber, a mineral, a plant alkaloid and bacteria, in various combinations. The panels we read included a three-strain probiotic capsule carrying 211 mg of chicory inulin, and a powdered blend selling on 6 grams of fiber per serving. The ingredient names that recur across the rest of the shelf are berberine, chromium, soluble fibers such as glucomannan or psyllium, green tea extract, cinnamon and inositol. None of those is a GLP-1 receptor agonist, which is why the marketing sentence is almost always about supporting the GLP-1 your body already makes rather than supplying any.
Does berberine work for weight loss?
The strongest available summary is a 2026 systematic review and meta-analysis of 23 randomized trials in the International Journal of Obesity, which found a mean weight reduction of 0.88 kg compared with control. NCCIH adds the context the label leaves off: effects appeared mainly in people taking more than a gram a day for more than eight weeks, many underlying studies carried a high risk of bias, and most were done in Asian countries in participants who already had diabetes or fatty liver disease. The meta-analysis itself asks future trials to report purity, potency and gram amounts.
What about chromium?
Chromium picolinate has a Cochrane systematic review covering nine randomized trials and 622 participants. Across all doses studied it found a mean difference of 1.1 kg after 12 to 16 weeks, which the review describes as of debatable clinical relevance, graded low-quality evidence. The authors' conclusion is a single sentence: they found no current, reliable evidence to inform firm decisions about the efficacy and safety of chromium picolinate supplements in overweight or obese adults.
Is any of it worth buying?
Fiber is, for what fiber does. Ramped slowly and with fluid, it addresses the constipation that sends most people shopping in the first place, and the mechanism there is real and well understood. Protein is worth the money for a different reason: appetite is the constraint, and protein-first eating protects what you would rather not lose. Electrolytes have a narrow, specific case. What is not worth buying is any of these ingredients priced as though it does what a prescription does.
Can I take one alongside my prescription?
That is a question for your prescriber and your pharmacist, and it is worth asking rather than assuming. Berberine is documented to interact with prescription medicines — NCCIH names cyclosporine — and it is described as likely unsafe for infants and possibly unsafe during pregnancy and breastfeeding. The reported side effects of berberine are also nausea, abdominal pain, bloating, constipation and diarrhea, which is the same list you may already be managing. Bring the actual bottle to the appointment.
Sources & further reading
We research from primary and authoritative sources. Where our guidance rests on a fact, here's where it comes from.
- FDA — Questions and Answers on Dietary Supplements — Source for the DSHEA framework: FDA does not have the authority to approve dietary supplements before they are marketed; a firm making a structure/function claim must hold substantiation but does not have to provide it to FDA; and FDA's one-word answer, No, to whether it routinely analyses the content of dietary supplements.
- Elahi Vahed I et al. — The effect of berberine on obesity indices: a systematic review and meta-analysis (International Journal of Obesity, 2026) — Source for the pooled mean weight reduction of 0.88 kg (95% CI −1.36 to −0.39) across 23 randomized trials, and for the authors' call for better reporting of purity, potency and gram amounts and for fixing the lack of blinding. Record confirmed via the EuropePMC REST API (PMID 41310257).
- NCCIH — Berberine and Weight Loss: What You Need To Know — Source for effects appearing mainly above one gram a day for more than eight weeks, the high risk of bias in included studies, the concentration of research in Asian countries and in participants with diabetes or fatty liver disease, the cyclosporine interaction, the infant and pregnancy cautions, and the reported gastrointestinal side effects.
- Tian H et al. — Chromium picolinate supplementation for overweight or obese adults (Cochrane Database of Systematic Reviews, 2013) — Source for the nine trials and 622 participants, the mean difference of −1.1 kg (95% CI −1.7 to −0.4) after 12 to 16 weeks described as of debatable clinical relevance on low-quality GRADE evidence, and the authors' conclusion that they found no current, reliable evidence to inform firm decisions. Record confirmed via the EuropePMC REST API (PMID 24293292).
- Zalewski BM et al. — The effect of glucomannan on body weight in overweight or obese children and adults: a systematic review of randomized controlled trials (Nutrition, 2015) — Source for the six included trials, the short-term body-weight reductions reported in three of the adult trials, and the finding that none of the trials reported a favourable effect on BMI. Record confirmed via the EuropePMC REST API (PMID 25701331).
- NCCIH — Green Tea: Usefulness and Safety — Source for the modest effect of catechins and caffeine on body weight, and for liver injury reported in some people using green tea extracts in tablet or capsule form.
- NCCIH — Weight Control — Source for the statements that analyses of dietary supplements sometimes find differences between labelled and actual ingredients, and that FDA has found weight-loss products tainted with prescription drug ingredients. Page last updated September 2017, which we say in the article.
- Aronne LJ et al. — Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5), New England Journal of Medicine 2025;393:26-36 — Used only for the scale comparison: 751 adults with obesity and without type 2 diabetes, mean weight change at week 72 of −20.2% with tirzepatide and −13.7% with semaglutide. Record confirmed via the EuropePMC REST API (PMID 40353578).
- FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — Source for the standing warning about counterfeit and fraudulent versions of these medications sold into the same demand these supplements ride.
LeanFed is not medical advice and is not a substitute for your prescriber, pharmacist or dietitian. We do not test products hands-on — we compare labels, specifications and owner reviews. Prices and LeanScores reflect our most recent research and refresh on a cycle; confirm the current price and read the product's own label before buying. We may earn a commission from affiliate retailers — it never changes our recommendations. See how we score.